Stocks Seattle Genetics Inc

  • At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.

  • TheStreet.com suggests stocks that could pop on their earnings reports.

  • 'Rare Good News' on Health Care Retirement Savings: Study

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • medicare.jpg

    TheStreet.com offers up 13 biotech predictions for 2013.

  • BOTHELL, Wash.-- Seattle Genetics Inc. said Tuesday that pharmaceutical giant Abbott Laboratories has agreed to pay $25 million plus potential milestone payments for the biotech firm's experimental antibodies to fight cancer.

  • The "Mad Money" host spoke with the CEO of Seattle Genetics about the safety of the biotech space.

  • Three laboratory technicians using microscope

    Savvy investors know that making money on the “ASCO trade” means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting.

  • finance_broker_desk2_200.jpg

    Hedge funds peeled back the curtain this week to reveal a bit about what biotech stocks they were buying and selling during the second quarter.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Traders are turning their attention to cancer-fighting companies, as the 2011 ASCO gets underway.

  • Cramer makes the call on viewers' favorite stocks.

  • Cramer makes the call on viewers' favorite stocks.

  • If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.

  • Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?

  • cadeuses2.jpg

    What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.

  • With the markets selling off again today, CNBC asked the experts for their best investment ideas now.

  • The Lightning Round is extended in this new CNBC.com exclusive feature.

  • biogenidec_AP.jpg

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • While on Capitol Hill the new Congress begins to take on the pharmaceuticals industry, the healthcare investment community is holding its annual confab in the hills of San Francisco--House Speaker Nancy Pelosi's home district. I'm at the 25th Annual JPMorgan Healthcare Conference at the Westin St. Francis on Union Square. The four-day event is just getting started, but the halls are...